Transaction
Pava Partners advised the shareholders of Genedata AG (“Genedata”), a leading provider of software solutions for biopharmaceutical R&D, on the sale to Danaher Corporation (NYSE: DHR) (“Danaher”), a leading global life sciences and diagnostics innovator.
This strategic acquisition presents an exciting opportunity for Genedata and Danaher to draw on their complementary strengths to drive life sciences innovation further. Genedata will operate as a standalone operating company and brand within Danaher’s Life Sciences segment. Genedata’s offerings are expected to add to Danaher’s broad workflow solutions that help accelerate the speed of drug discovery, development, and manufacturing for critical new therapies.
Founded in 1997 and headquartered in Basel, Switzerland, Genedata is at the forefront of transforming data into intelligence for the life sciences industry. Genedata delivers scalable and open solutions that enhance R&D productivity, serving top global biopharmaceutical companies and innovative biotechnology organizations around the globe. Over the last few years, and prior to this transaction, Genedata and Danaher have engaged in several successful collaborations.
“Genedata is a global market leader in digitalizing R&D processes to help accelerate the delivery of lifesaving and personalized medicines. Our achievements are driven by the dedication and expertise of our teams, whose efforts have been instrumental in earning the trust of our customers,” said Othmar Pfannes, Ph.D., Founder and CEO of Genedata. “As a Danaher operating company, Genedata will seek to continue to attract the brightest talent and solve our customers’ hardest problems globally.”
“Throughout our trusted relationship with Genedata, we have long admired their innovative software systems anchored in deep scientific expertise. We share a commitment to supporting biopharma companies to accelerate the development of much-needed therapies by providing innovative solutions that help researchers access high-quality insights,” said Greg Milosevich, Vice President and Group Executive of Danaher’s DH Life Sciences LLC subsidiary. “We are excited to welcome their team to Danaher and intend to continue expanding Genedata’s capabilities to address new technologies and requirements in this quickly evolving field.”
Client
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help support the return-on-investment attributable to R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
Explore more at www.genedata.com
Buyer
About Danaher Corporation
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to help solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our 65,000+ associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow.
Explore more at www.danaher.com